Pharmacopeia Announces Upcoming Late-Breaker Presentation Of Phase 2a Results For Its First-in-Class Investigational DARA Compound, PS433540
April 17th, 2008 by samospsipsi
Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced that results from the company’s Phase 2a clinical trial evaluating PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), will be presented as a late-breaking clinical trial at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition in New Orleans, May 14-17, 2008.
More: continued here
